SIT Antibody (G-8): sc-271202
- SIT Antibody (G-8) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 1-196 representing full length SIT of human origin
- recommended for detection of SIT of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for SIT Antibody (G-8) for WB applications. These reagents are now offered in bundles with SIT Antibody (G-8) (see ordering information below).
QUICK LINKS
SEE ALSO...
SIT Antibody (G-8) is a mouse monoclonal IgG1 antibody that detects SIT in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). SIT, or SHP2 interacting transmembrane adaptor protein, plays a crucial role in T lymphocyte signaling by acting as a disulfide-linked homodimeric glycoprotein that facilitates the recruitment of SH2 domain-containing intracellular signaling molecules to the plasma membrane via tyrosine-based signaling pathways. The presence of five potential tyrosine phosphorylation sites on SIT indicates its importance in T cell receptor-mediated signaling, which is vital for effective immune responses. Additionally, SIT interacts with key proteins such as SHP2 and the adaptor protein Grb2, and serves as a substrate for Src family kinases, including Fyn, Lck, and ZAP-70, which are essential for T cell activation and function. The ability of SIT to undergo endoglycosidase treatment, resulting in a reduction of its molecular mass, further highlights its dynamic role in cellular signaling processes. Anti-SIT antibody (G-8) is an invaluable tool for researchers studying T cell signaling pathways and their implications in immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
SIT Antibody (G-8) References:
- Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. | Parks, KW. and Casale, TB. 2006. Allergy Asthma Proc. 27: S33-6. PMID: 16722330
- SIT beyond respiratory diseases. | Pajno, GB. and Finegold, I. 2011. Ann Allergy Asthma Immunol. 107: 395-400. PMID: 22018609
- Antisperm antibodies. | Cropp, CS. and Schlaff, WD. 1990. Arch Immunol Ther Exp (Warsz). 38: 31-46. PMID: 2288473
- Epitope specificity determines cross-protection of a SIT-induced IgG4 antibody. | Gadermaier, E., et al. 2016. Allergy. 71: 36-46. PMID: 26221749
- Allergen-specific immunotherapy: is it vaccination against toxins after all? | Bachmann, MF. and Kündig, TM. 2017. Allergy. 72: 13-23. PMID: 27558586
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. | Gerstein, HC., et al. 2019. Lancet. 394: 121-130. PMID: 31189511
- Ageing hallmarks exhibit organ-specific temporal signatures. | Schaum, N., et al. 2020. Nature. 583: 596-602. PMID: 32669715
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. | Pusztai, L., et al. 2021. Cancer Cell. 39: 989-998.e5. PMID: 34143979
- Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. | Ng, SC., et al. 2022. Gut. 71: 1106-1116. PMID: 35140064
- NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. | Feng, W., et al. 2023. Nat Commun. 14: 7238. PMID: 37945559
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SIT Antibody (G-8) | sc-271202 | 200 µg/ml | $322.00 | |||
SIT Antibody (G-8): m-IgG Fc BP-HRP Bundle | sc-537587 | 200 µg Ab; 10 µg BP | $361.00 | |||
SIT Antibody (G-8): m-IgGκ BP-HRP Bundle | sc-534893 | 200 µg Ab; 40 µg BP | $361.00 | |||
SIT Antibody (G-8): m-IgG1 BP-HRP Bundle | sc-545246 | 200 µg Ab; 20 µg BP | $361.00 |